Karyopharm Therapeutics Files for Bankruptcy and Announces Merger with Ayrmid
Karyopharm Therapeutics (KPTI) has announced its intention to file for bankruptcy protection as part of a strategic plan to merge with Ayrmid. To support the restructuring process, the company has secured commitments for up to $55 million in debtor-in-possession (DIP) financing from its current secured lenders. The move represents a significant restructuring effort aimed at stabilizing the company's financial position through the merger. The implementation of the DIP financing and the subsequent merger are subject to court approval.
Tickers: $KPTI
Topics: bankruptcy filing DIP financing merger